Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 10 records in total 81
    records per page

    Kinetics of SARS-CoV-2 Antibody SERO Avidity Maturation and Association with Disease MESHD Severity

    Authors: Yiqi Ruben Luo; Indrani Chakraborty; Cassandra Yun; Alan H.B. Wu; Kara Lake Lynch

    doi:10.1101/2020.07.30.20165522 Date: 2020-08-02 Source: medRxiv

    The kinetics of immunoglobulin G (IgG) avidity maturation during severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) infection MESHD was studied. The IgG avidity assay used a novel label-free immunoassay SERO technology to test IgG against the virus spike protein receptor-binding domain (RBD). The technology, thin-film interferometry (TFI), is able to sense the formation of immune complex on a sensing probe without attaching a reporter (enzyme, fluorophore, etc.). It was found that there was a strong correlation between IgG antibody SERO avidity and days since symptom onset TRANS (p < 0.0001). In addition, peak readings were significantly higher for specimens from ICU than non-ICU patients for the first month after symptom onset TRANS (1-4 weeks) and thereafter (p<0.0001). The findings are consistent for what has been reported for SARS-CoV. Given that SARS-CoV-2 specific IgG avidity is strong in ICU patients after 1 month, this suggests that antibody SERO-mediated immune enhancement triggered by suboptimal antibodies SERO may not play a role in COVID-19 disease progression MESHD and severity.

    Comparison of sixteen serological SARS-CoV-2 immunoassays SERO in sixteen clinical laboratories

    Authors: Lene Holm Harritshoej; Mikkel Gybel-Brask; Shoaib Afzal; Pia R. Kamstrup; Charlotte Svaerke Joergensen; Marianne K. Thomsen; Linda M. Hilsted; Lennart J. Friis-Hansen; Pal B. Szecsi; Lise Pedersen; Lene Nielsen; Cecilie B. Hansen; Peter Garred; Trine-Line Korsholm; Susan Mikkelsen; Kirstine O. Nielsen; Bjarne K. Moeller; Anne T. Hansen; Kasper K. Iversen; Pernille B. Nielsen; Rasmus B. Hasselbalch; Kamille Fogh; Jakob B. Norsk; Jonas H. Kristensen; Kristian Schoenning; Nikolai S. Kirkby; Alex C.Y. Nielsen; Lone H. Landsy; Mette Loftager; Dorte K. Holm; Anna C. Nilsson; Susanne G. Saekmose; Birgitte Grum-Svendsen; Bitten Aagaard; Thoeger G. Jensen; Dorte M. Nielsen; Henrik Ullum; Ram BC Dessau

    doi:10.1101/2020.07.30.20165373 Date: 2020-08-02 Source: medRxiv

    Serological SARS-CoV-2 assays are needed to support clinical diagnosis and epidemiological investigations. Recently, assays for the large-volume detection of total antibodies SERO (Ab) and immunoglobulin (Ig) G and M against SARS-CoV-2 antigens have been developed, but there are limited data on the diagnostic accuracy of these assays. This study was organized as a Danish national collaboration and included fifteen commercial and one in-house anti-SARS-CoV-2 assays in sixteen laboratories. Sensitivity SERO was evaluated using 150 serum samples SERO from individuals diagnosed with asymptomatic TRANS, mild or moderate nonhospitalized (n=129) or hospitalized (n=31) COVID-19, confirmed by nucleic acid amplification tests, collected 13-73 days from symptom onset TRANS. Specificity and cross-reactivity were evaluated in samples collected prior to the SARS-CoV-2 epidemic from > 586 blood SERO donors and patients with autoimmune diseases MESHD or CMV or EBV infections MESHD. Predefined specificity criteria of [≥]99% were met by all total-Ab and IgG assays except one (Diasorin/LiaisonXL-IgG 97.2%). The sensitivities SERO in descending order were: Wantai/ ELISA SERO total-Ab (96.7%), CUH/NOVO in-house ELISA SERO total-Ab (96.0%), Ortho/Vitros total-Ab (95.3%), YHLO/iFlash-IgG (94.0%), Ortho/Vitros-IgG (93.3%), Siemens/Atellica total-Ab (93.2%), Roche-Elecsys total-Ab (92.7%), Abbott-Architect-IgG (90.0%), Abbott/Alinity-IgG (median 88.0%), Diasorin/LiaisonXL-IgG (84.6%), Siemens/Vista total-Ab (81.0%), Euroimmun/ ELISA-IgG SERO (78.0%), and Snibe/Maglumi-IgG (median 78.0%). The IgM results were variable, but one assay (Wantai/ ELISA SERO-IgM) had both high sensitivity SERO (82.7%) and specificity (99%). The rate of seropositivity increased with time from symptom onset TRANS and symptom severity. In conclusion, predefined sensitivity SERO and specificity acceptance criteria of 90%/99%, respectively, for diagnostic use were met in five of six total-Ab and three of seven IgG assays.

    A High-throughput Anti-SARS-CoV-2 IgG Testing Platform for COVID-19

    Authors: Jinwei Du; Eric Chu; Dayu Zhang; Chuanyi M Lu; Aiguo Zhang; Michael Y. Sha

    doi:10.1101/2020.07.23.20160804 Date: 2020-07-27 Source: medRxiv

    Background: Serology tests for detecting the antibodies SERO to severe acute respiratory syndrome MESHD coronavirus 2 (SARS-CoV-2) can identify previous infection MESHD and help to confirm the presence of current infection MESHD. Objective: The aim of this study was to evaluate the performances SERO of a newly developed high throughput immunoassay SERO for anti-SARS-CoV-2 IgG antibody SERO detection. Results: Clinical agreement studies were performed in 77 COVID-19 patient serum samples SERO and 226 negative donor serum SERO/ plasma SERO samples. Positive percent agreement (PPA) was 42.86% (95% CI: 9.90% to 81.59%), 55.56% (95% CI: 21.20% to 86.30%), and 96.72% (95% CI: 88.65% to 99.60%) for samples collected on 0-7 days, 8-14 days, and [≥]15 days from symptom onset TRANS, respectively. Negative Percent Agreement (NPA) was 98.23% (95% CI: 95.53% to 99.52%). No cross-reactivity was observed to patient samples positive for IgG antibodies SERO against the following pathogens: HIV, HAV, HBV, RSV, CMV, EBV, Rubella MESHD, Influenza A, and Influenza B. Hemoglobin (200 mg/dL), bilirubin (2 mg/dL) and EDTA (10 mM) showed no significant interfering effect on this assay. Conclusion: An anti-SARS-CoV-2 IgG antibody SERO assay with high sensitivity SERO and specificity has been developed. With the high throughput, this assay will speed up the anti-SARS-CoV-2 IgG testing.

    SARS-CoV-2 antibodies SERO, serum SERO inflammatory biomarkers and clinical severity of hospitalized COVID-19 Patients

    Authors: Roberto Gozalbo-Rovira; Estela Gimenez; Victor Latorre; Clara Frances-Gomez; Eliseo Albert; Javier Buesa; Alberto Marina; Maria Luisa Blasco; Jaime Signes-Costa; Jesus Rodriguez-Diaz; Ron Geller; David Navarro

    doi:10.1101/2020.07.22.20159673 Date: 2020-07-24 Source: medRxiv

    Background: The involvement of SARS-CoV-2 antibodies SERO in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies SERO (NtAb) targeting S, and COVID-19 severity. Patients and Methods: This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms TRANS were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA SERO and NtAb50 titers were measured in a GFP reporter-based pseudotyped virus platform. Demographic and clinical data, complete blood SERO counts, as well as serum SERO levels of ferritin, Dimer-D, C reactive protein (CRP), lactose dehydrogenase (LDH), and interleukin-6 (IL-6) were retrieved from clinical charts. Results: The overall correlation between levels of both antibody SERO measurements was good (Rho=0.79; P=0<0.001). SARS-CoV-2 RBD IgG and NtAb50 levels in sera collected up to day 30 after the onset of symptoms TRANS were comparable between ICU and non-ICU patients (P=>0.1). The percentage of patients who exhibited high NtAb50 titers ([≥]160) was similar (P=0.20) in ICU (79%) and non-ICU (60%) patients. Four ICU patients died; two of these achieved NtAb50 titers [≥]1/160 while the other two exhibited a 1/80 titer. Very weak (Rho=>0.0-<0.2) or weak (Rho=>0.2-<0.4) correlations were observed between anti-RBD IgGs, NtAb50, and serum SERO levels pro-inflammatory biomarkers. Conclusions: The data presented herein do not support an association between SARS-CoV-2 RBD IgG or NtAb50 levels and COVID-19 severity

    Kinetics and Isotype Assessment of Antibodies SERO Targeting the Spike Protein Receptor Binding Domain of SARS-CoV-2 In COVID-19 Patients as a function of Age TRANS and Biological Sex.

    Authors: Nancy R. Graham; Annalis N. Whitaker; Camilla A. Strother; Ashley K. Miles; Dore Grier; Benjamin D. McElvany; Emily A Bruce; Matthew E. Poynter; Kristen K. Pierce; Beth D. Kirkpatrick; Renee D. Stapleton; Gary An; Jason W. Botten; Jessica W. Crothers; Sean A. Diehl

    doi:10.1101/2020.07.15.20154443 Date: 2020-07-22 Source: medRxiv

    SARS-CoV-2 is the newly emerged virus responsible for the global COVID-19 pandemic. There is an incomplete understanding of the host humoral immune response to SARS-CoV-2 during acute infection MESHD. Host factors such as age TRANS and sex as well the kinetics and functionality of antibody SERO responses are important factors to consider as vaccine development proceeds. The receptor-binding domain of the CoV spike (RBD-S) protein is important in host cell recognition and infection MESHD and antibodies SERO targeting this domain are often neutralizing. In a cross-sectional study of anti-RBD-S antibodies SERO in COVID-19 patients we found equivalent levels in male TRANS and female TRANS patients and no age TRANS-related deficiencies even out to 93 years of age TRANS. The anti-RBD-S response was evident as little as 6 days after onset of symptoms TRANS and for at least 5 weeks after symptom onset TRANS. Anti-RBD-S IgG, IgM, and IgA responses were simultaneously induced within 10 days after onset, but isotype-specific kinetics differed such that anti-RBD-S IgG was most sustained over a 5-week period. The kinetics and magnitude of neutralizing antibody SERO formation strongly correlated with that seen for anti-RBD-S antibodies SERO. Our results suggest age TRANS- and sex- related disparities in COVID-19 fatalities are not explained by anti-RBD-S responses. The multi-isotype anti-RBD-S response induced by live virus infection MESHD could serve as a potential marker by which to monitor vaccine-induced responses.

    Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2.

    Authors: Marina Johnson; Helen Wagstaffe; Kimberly C Gilmour; Annabelle Lea Mai; Joanna Lewis; Adam Hunt; Jake Sirr; Christopher Bengt; Louis Grandjean; David Goldblatt

    doi:10.1101/2020.07.20.213249 Date: 2020-07-21 Source: bioRxiv

    BackgroundThe emergence of SARS-CoV-2 has led to the development of new serological assays SERO that could aid in diagnosis and evaluation of seroprevalence SERO to inform an understanding of the burden of COVID-19 disease MESHD. Many available tests lack rigorous evaluation and therefore results may be misleading. ObjectivesThe aim of this study was to assess the performance SERO of a novel multiplexed immunoassay SERO for the simultaneous detection of antibodies SERO against SARS-CoV-2 trimeric spike (S), spike receptor binding domain (RBD), spike N terminal domain and nucleocapsid antigen and a novel pseudo-neutralisation assay. MethodsA multiplexed solid-phase chemiluminescence assay (Meso Scale Discovery) was evaluated for the simultaneous detection of IgG binding to four SARS-CoV-2 antigens and the quantification of antibody SERO-induced ACE-2 binding inhibition (pseudo-neutralisation assay). Sensitivity SERO was evaluated with a total of 196 COVID-19 serum samples SERO (169 confirmed PCR positive and 27 anti-nucleocapsid IgG positive) from individuals with mild symptomatic or asymptomatic disease MESHD asymptomatic TRANS. Specificity was evaluated with 194 control serum samples SERO collected from adults TRANS prior to December 2019. ResultsThe specificity and sensitivity SERO of the binding IgG assay was highest for S protein with a specificity of 97.4% and sensitivity SERO of 96.2% for samples taken 14 days and 97.9% for samples taken 21 days following the onset of symptoms TRANS. IgG concentration to S and RBD correlated strongly with percentage inhibition measured by the pseudo-neutralisation assay. ConclusionExcellent sensitivity SERO for IgG detection was obtained over 14 days since onset of symptoms TRANS for three SARS-CoV-2 antigens (S, RBD and N) in this multiplexed assay which can also measure antibody SERO functionality.

    The change pattern and significance of IgM and IgG in the progress of COVID-19 disease MESHD

    Authors: Xuzhen Qin; Jun Shen; Erhei Dai; Haolong Li; Guodong Tang; Lixia Zhang; Xin Hou; Minya Lu; Xian Wu; Simeng Duan; Jingjia Zhang; Yongzhe Li

    doi:10.1101/2020.07.20.20157446 Date: 2020-07-21 Source: medRxiv

    Background: To investigate the significance of IgM and IgG in the progress of COVID-19. Method: A multicenter cross-sectional study conducted in suspected and confirmed patients from four hospitals of China and a cohort study to identify the change pattern and significance in the process of COVID-19 disease MESHD. Results: A total of 571 patients were enrolled in the cross-sectional study, including 235 confirmed SARS-CoV-2 infection MESHD with 91.9% patients IgG positive and 92.3% IgM positive. 30 patients diagnosed with SARS-CoV-2 infection MESHD were enrolled in the cohort study for flowing-up in 20 days. The peak of IgM and IgG reached in 10th and 20 th day separately after symptom onset TRANS. The relationship between clinical classification and serological antibodies SERO were analysed. The positive rate of COVID-19 IgG and IgM increased along with the clinical classification and the delay of treatment time. Conclusion: We demonstrated the kinetics of IgM and IgG SARS-CoV-2 antibody SERO in COVID-19 patients, which may contribute to explain the results of IgM and IgG SARS-CoV-2 antibody SERO test and predict the prognosis of COVID-19.

    Dynamics and significance of the antibody SERO response to SARS-CoV-2 infection MESHD

    Authors: Anita S Iyer; Forrest K Jones; Ariana Nodoushania; Meagan Kelly; Margaret Becker; Damien Slater; Rachel Mills; Erica Teng; Mohammad Kamruzzaman; Wilfredo F Garcia-Beltran; Michael Astudillo; Diane Yang; Tyler E Miller; Elizabeth Oiver; Stephanie Fischinger; Caroline Atyeo; Anthony John Iafrate; Stephen B Calderwood; Stephen A Lauer; Jingyou Yu; Zhenfeng Li; Jared Feldman; Blake M Hauser; Timothy M Cardonna; John A Branda; Sarah E Turbett; Regina C LaRocque; Guillaume Mellon; Dan H Barouch; Aaron G Schmidt; Andrew S Azman; Galit Alter; Edward T Ryan; Jason B Harris; Richelle C Charles

    doi:10.1101/2020.07.18.20155374 Date: 2020-07-20 Source: medRxiv

    BACKGROUND Characterizing the humoral immune response to SARS-CoV-2 and developing accurate serologic assays are needed for diagnostic purposes and estimating population-level seroprevalence SERO. METHODS We measured the kinetics of early antibody SERO responses to the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 in a cohort of 259 symptomatic North American patients infected with SARS-CoV-2 (up to 75 days after symptom onset TRANS) compared to antibody SERO levels in 1548 individuals whose blood SERO samples were obtained prior to the pandemic. RESULTS Between 14-28 days from onset of symptoms TRANS, IgG, IgA, or IgM antibody SERO responses to RBD were all accurate in identifying recently infected individuals, with 100% specificity and a sensitivity SERO of 97%, 91%, and 81% respectively. Although the estimated median time to becoming seropositive was similar across isotypes, IgA and IgM antibodies SERO against RBD were short-lived with most individuals estimated to become seronegative again by 51 and 47 days after symptom onset TRANS, respectively. IgG antibodies SERO against RBD lasted longer and persisted through 75 days post-symptoms. IgG antibodies SERO to SARS-CoV-2 RBD were highly correlated with neutralizing antibodies SERO targeting the S protein. No cross-reactivity of the SARS-CoV-2 RBD-targeted antibodies SERO was observed with several known circulating coronaviruses, HKU1, OC 229 E, OC43, and NL63. CONCLUSIONS Among symptomatic SARS-CoV-2 cases, RBD-targeted antibodies SERO can be indicative of previous and recent infection MESHD. IgG antibodies SERO are correlated with neutralizing antibodies SERO and are possibly a correlate of protective immunity.

    Longitudinal analysis of the humoral response to SARS-CoV-2 spike RBD in convalescent plasma SERO donors

    Authors: Josée Perreault; Tony Tremblay; Marie-Josée Fournier; Mathieu Drouin; Guillaume Beaudoin-Bussières; Jérémie Prévost; Antoine Lewin; Philippe Bégin; Andrés Finzi; Renée Bazin

    doi:10.1101/2020.07.16.206847 Date: 2020-07-17 Source: bioRxiv

    Hema-Quebec, the blood SERO supplier in the Province of Quebec, Canada, collects and tests convalescent plasma SERO used in a clinical trial to determine the clinical efficacy of this product for the treatment of hospitalized COVID-19 patients. So far, we have collected 1159 plasma SERO units from 282 COVID-19 convalescent donors. The presence of antibodies SERO to the receptor binding domain (RBD) of SARS-CoV-2 spike protein in convalescent donors was established at the first donation. Seropositive donors were asked to donate additional plasma SERO units every six days. Until now, 15 donors have donated at least four times and, in some cases, up to nine times. This allowed us to perform a longitudinal analysis of the persistence of SARS-CoV-2 RBD-specific antibodies SERO in these repeat donors, with the first donation occurring 33-77 days after symptoms onset TRANS and donations up to 71-114 days after symptoms onset TRANS thereafter. In all donors, the level of antibodies SERO remained relatively stable up to about 76 days after symptoms onset TRANS but then started to decrease more rapidly to reach, in some convalescent donors, a seronegative status within 100-110 days after symptoms onset TRANS. The decline in anti-RBD antibodies SERO was not related to the number of donations but strongly correlated with the numbers of days after symptoms onset TRANS (r = 0.821). This suggests that de novo secretion of SARS-CoV-2 RBD antibodies SERO by short-lived plasma SERO cells stopped about 2-3 months after disease MESHD onset, an observation that has important implications for convalescent plasma SERO collection and seroprevalence SERO studies undertaken several months after the peak of infection MESHD.

    Longitudinal dynamics of the neutralizing antibody SERO response to SARS-CoV-2 infection MESHD

    Authors: Kai Wang; Quan-Xin Long; Hai-Jun Deng; Jie Hu; Qing-Zhu Gao; Gui-Ji Zhang; Chang-Long He; Lu-Yi Huang; Jie-Li Hu; Juan Chen; Ni Tang; Ai-Long Huang

    doi:10.1101/2020.07.14.20151159 Date: 2020-07-17 Source: medRxiv

    Background Coronavirus disease MESHD 2019 (COVID-19) is a global pandemic with no licensed vaccine or specific antiviral agents for therapy. Little is known about the longitudinal dynamics of SARS-CoV-2-specific neutralizing antibodies SERO (NAbs) in COVID-19 patients. Methods Blood SERO samples (n=173) were collected from 30 COVID-19 patients over a 3-month period after symptom onset TRANS and analyzed for SARS-CoV-2-specific NAbs, using the lentiviral pseudotype assay, coincident with the levels of IgG and proinflammatory cytokines. Results SARS-CoV-2-specific NAb titers were low for the first 7-10 d after symtom onset and increased after 2-3 weeks. The median peak time for NAbs was 33 d (IQR 24-59 d) after symptom onset TRANS. NAb titers in 93.3% (28/30) of the patients declined gradually over the 3-month study period, with a median decrease of 34.8% (IQR 19.6-42.4%). NAb titers increased over time in parallel with the rise in IgG antibody SERO levels, correlating well at week 3 (r = 0.41, p < 0.05). The NAb titers also demonstrated a significant positive correlation with levels of plasma SERO proinflammatory cytokines, including SCF, TRAIL, and M-CSF. Conclusions These data provide useful information regarding dynamic changes in NAbs in COVID-19 patients during the acute and convalescent phases.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.